Treatment of pulmonary arterial hypertension due to scleroderma: challenges for the future.
Although progress has been made in treatment of pulmonary arterial hypertension, serious challenges remain. This article provides an overview of the challenges faced in treatment of PAH caused by scleroderma. It also provides a glimpse into the future, based on recent developments in the field that hold promise for enhancing the treatment of this disease.
Rubin
Lewis J
LJ
University of California, San Diego School of Medicine, 9300 Campus Point Drive, La Jolla, CA 92032, USA. ljrubin@ucsd.edu
D053898:Biosynthetic Pathways / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*; D007155:Immunologic Factors; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D012595:Scleroderma, Systemic / Q000150:complications / Q000503:physiopathology*
D007155:Immunologic Factors